Dova Pharmaceuticals (DOVA) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- US stock index futures slip as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results
November 9, 2017 4:05 PM ESTNDA for avatrombopag submitted to FDA
Conference call scheduled for 4:30 p.m. EST today
DURHAM, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today reported its operating and financial results for the quarter ended September 30, 2017.
Third Quarter and Recent Highlights
Submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Dova's drug candidate, avatrombopag, for the treatment of thrombocytopenia in... More